Corpus ID: 29285039

SJ-3366 Sam Jin Pharmaceutical.

@article{Baba2002SJ3366SJ,
  title={SJ-3366 Sam Jin Pharmaceutical.},
  author={M. Baba},
  journal={Current opinion in investigational drugs},
  year={2002},
  volume={3 8},
  pages={
          1146-8
        }
}
  • M. Baba
  • Published 2002
  • Medicine
  • Current opinion in investigational drugs
Sam Jin is investigating SJ-3366, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for the potential treatment of HIV infection [302450]. As well as acting as an NNRTI, SJ-3366 also interferes with HIV-1 entry via an intermediate target formed after virus-cell attachment [341146], [363900]. As of June 1998, Sam Jin had been awarded a patent for SJ-3366 in South Africa, with applications pending in 22 other countries [302450]. 
1 Citations
The development of HEPT-type HIV non-nucleoside reverse transcriptase inhibitors and its implications for DABO family.
TLDR
An insight is provided into the development of HEPT, including structural modifications, crystal structure of RT complexed with HEPTs and its structure-activity relationship (SAR), as well as the contributions of H EPTs to theDevelopment of dihydro-alkoxy-benzyl-oxopyrimidine (DABO) family. Expand